Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give Janux a consensus rating of "Moderate Buy" from 14 firms (11 buys, 2 holds, 1 sell) with an average 12‑month price target of $56.91, versus the stock's recent open near $14.06.
• Janux beat quarterly expectations, reporting EPS of ($0.51) vs. ($0.65) estimated and revenue of $7.88 million versus $0.08 million expected.
• There has been recent insider selling (19,033 shares sold in the last 90 days) even as institutional investors hold a large stake in the company (about 75% ownership).

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the fourteen ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $56.9091.

A number of equities research analysts recently issued reports on the company. Stifel Nicolaus reduced their target price on Janux Therapeutics from $46.00 to $38.00 and set a "buy" rating on the stock in a research note on Tuesday, December 2nd. Cantor Fitzgerald dropped their price target on Janux Therapeutics from $150.00 to $100.00 and set an "overweight" rating for the company in a research report on Friday, February 27th. UBS Group reissued a "buy" rating and issued a $57.00 price target on shares of Janux Therapeutics in a report on Tuesday, December 2nd. Piper Sandler reduced their price objective on Janux Therapeutics from $42.00 to $30.00 and set an "overweight" rating on the stock in a research report on Friday, January 16th. Finally, Clear Str lowered Janux Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, January 20th.

Janux Therapeutics Trading Down 0.7%

NASDAQ:JANX opened at $14.06 on Monday. The company has a market capitalization of $855.27 million, a P/E ratio of -7.68 and a beta of 2.88. The firm has a 50-day moving average price of $13.71 and a two-hundred day moving average price of $19.63. Janux Therapeutics has a twelve month low of $12.12 and a twelve month high of $35.34.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.14. The business had revenue of $7.88 million during the quarter, compared to analysts' expectations of $0.08 million. On average, equities research analysts predict that Janux Therapeutics will post -1.38 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Charles M. Winter sold 2,401 shares of the business's stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $32,965.73. Following the completion of the transaction, the insider owned 77,721 shares of the company's stock, valued at $1,067,109.33. The trade was a 3.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Zachariah Mciver sold 2,714 shares of the business's stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total transaction of $37,263.22. Following the completion of the transaction, the insider directly owned 23,286 shares of the company's stock, valued at approximately $319,716.78. This represents a 10.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 19,033 shares of company stock worth $261,323 in the last 90 days. 29.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Janux Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC boosted its holdings in shares of Janux Therapeutics by 230.0% during the second quarter. Squarepoint Ops LLC now owns 189,569 shares of the company's stock worth $4,379,000 after purchasing an additional 132,121 shares during the last quarter. Aberdeen Group plc increased its stake in Janux Therapeutics by 21.1% in the third quarter. Aberdeen Group plc now owns 345,476 shares of the company's stock valued at $8,443,000 after purchasing an additional 60,188 shares during the last quarter. Geode Capital Management LLC increased its stake in Janux Therapeutics by 15.5% in the second quarter. Geode Capital Management LLC now owns 902,312 shares of the company's stock valued at $20,845,000 after purchasing an additional 121,403 shares during the last quarter. Capital Fund Management S.A. purchased a new position in Janux Therapeutics during the second quarter worth about $757,000. Finally, Congress Asset Management Co. purchased a new position in Janux Therapeutics during the third quarter worth about $1,363,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.